menu
    • menu

    Company profile for Revance Therapeutics

    NEW Drugs in Dev: 6
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Revance is more than a biotechnology company taking an innovative approach to neuromodulator delivery. We are the integrated sum of our many strengths. Deep knowledge of drug development, scientific acumen, and prior commercialization experience will enable our team of experts to bring to market a focused portfolio of product candidates that achieve multiple strategic objectives. Our trajectory to commercial success begins wit...
    Revance is more than a biotechnology company taking an innovative approach to neuromodulator delivery. We are the integrated sum of our many strengths. Deep knowledge of drug development, scientific acumen, and prior commercialization experience will enable our team of experts to bring to market a focused portfolio of product candidates that achieve multiple strategic objectives. Our trajectory to commercial success begins with the development and delivery of our next-generation neuromodulator, daxibotulinumtoxinA, Revance’s highly purified botulinum toxin type A.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Revance TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7555 Gateway Boulevard Newark, California 94560
    Telephone
    Telephone
    (510) 742-3400
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.revance.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crown Laboratories Completes Acquisition of Revance Therapeutics
    Crown Laboratories Completes Acquisition of Revance Therapeutics

    07 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250207314086/en

    BUSINESSWIRE
    07 Feb 2025
    Share Share
    Dermata & Revance Enter Trial Agreement For Xyngari™ & Daxxify®
    Dermata & Revance Enter Trial Agreement For Xyngari™ & Daxxify®

    21 Jan 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-01-21/dermata-and-revance-enter-clinical-trial-collaboration-agreement-for-the-topical-application-of-xyng

    PHARMAWEB
    21 Jan 2025
    Share Share
    Revance Reports Q3 2024 Financial Results, Corporate Update
    Revance Reports Q3 2024 Financial Results, Corporate Update

    07 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241107685733/en

    BUSINESSWIRE
    07 Nov 2024
    Share Share
    Revance Agrees To $924M Buyout By Crown Laboratories
    Revance Agrees To $924M Buyout By Crown Laboratories

    13 Aug 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/daxxify-maker-revance-agrees-924m-buyout-private-skincare-company-crown-laboratories?itm_source=parsely-api

    FIERCE PHARMA
    13 Aug 2024
    Share Share
    Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
    Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update

    08 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240808615004/en

    BUSINESSWIRE
    08 Aug 2024
    Share Share
    Revance To Report Q2 2024 Results On August 8
    Revance To Report Q2 2024 Results On August 8

    01 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240801872014/en

    BUSINESSWIRE
    01 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search